Iovance Biotherapeutics Inc (IOVA)

[GMH*]

Biggest comments on the call for me:

1) Continued acceleration of patient enrollments
2) Expansion of approved ATCs to 70 by year-end because of interest from Cancer Centers - expected this but glad to hear it communicated
3) Progress made on NSCLC, especially when they said that P2 may be registrational.
4) Initiation of IOV-5001 using IL-12 rather than IL-2. IL-12 also seems to reinvigorate NK cells. - will need to read up a bit more on this and will share what I find later.